These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 2879325)

  • 21. Spiperone: influence of spiro ring substituents on 5-HT2A serotonin receptor binding.
    Metwally KA; Dukat M; Egan CT; Smith C; DuPre A; Gauthier CB; Herrick-Davis K; Teitler M; Glennon RA
    J Med Chem; 1998 Dec; 41(25):5084-93. PubMed ID: 9836624
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lack of a difference between ketanserin and ritanserin in central vs. peripheral serotonin receptor antagonism.
    Cohen ML; Bloomquist WL; Snoddy HD; Fuller RW
    Life Sci; 1989; 45(13):1185-9. PubMed ID: 2507847
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Repeated administration of pergolide to rats attenuates the acute elevation of serum corticosterone by pergolide.
    Fuller RW; Snoddy HD
    Pharmacol Biochem Behav; 1981 Dec; 15(6):933-6. PubMed ID: 7323119
    [TBL] [Abstract][Full Text] [Related]  

  • 24. New antipsychotic agents with serotonin and dopamine antagonist properties based on a pyrrolo[2,1-b][1,3]benzothiazepine structure.
    Campiani G; Nacci V; Bechelli S; Ciani SM; Garofalo A; Fiorini I; Wikström H; de Boer P; Liao Y; Tepper PG; Cagnotto A; Mennini T
    J Med Chem; 1998 Sep; 41(20):3763-72. PubMed ID: 9748351
    [TBL] [Abstract][Full Text] [Related]  

  • 25. LY53857, a selective and potent serotonergic (5-HT2) receptor antagonist, does not lower blood pressure in the spontaneously hypertensive rat.
    Cohen ML; Fuller RW; Kurz KD
    J Pharmacol Exp Ther; 1983 Nov; 227(2):327-32. PubMed ID: 6313898
    [TBL] [Abstract][Full Text] [Related]  

  • 26. KKHA-761, a potent D3 receptor antagonist with high 5-HT1A receptor affinity, exhibits antipsychotic properties in animal models of schizophrenia.
    Park WK; Jeong D; Cho H; Lee SJ; Cha MY; Pae AN; Choi KI; Koh HY; Kong JY
    Pharmacol Biochem Behav; 2005 Oct; 82(2):361-72. PubMed ID: 16216322
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preclinical pharmacology of FMPD [6-fluoro-10-[3-(2-methoxyethyl)-4-methyl-piperazin-1-yl]-2-methyl-4H-3-thia-4,9-diaza-benzo[f]azulene]: a potential novel antipsychotic with lower histamine H1 receptor affinity than olanzapine.
    Rasmussen K; Benvenga MJ; Bymaster FP; Calligaro DO; Cohen IR; Falcone JF; Hemrick-Luecke SK; Martin FM; Moore NA; Nisenbaum LK; Schaus JM; Sundquist SJ; Tupper DE; Wiernicki TR; Nelson DL
    J Pharmacol Exp Ther; 2005 Dec; 315(3):1265-77. PubMed ID: 16141369
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 1-(1-Naphthyl)piperazine, a central serotonin agonist.
    Fuller RW; Mason NR; Snoddy HD; Perry KW
    Res Commun Chem Pathol Pharmacol; 1986 Jan; 51(1):37-45. PubMed ID: 2419952
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [35S]Guanosine-5'-O-(3-thio)triphosphate binding as a measure of efficacy at human recombinant dopamine D4.4 receptors: actions of antiparkinsonian and antipsychotic agents.
    Newman-Tancredi A; Audinot V; Chaput C; Verrièle L; Millan MJ
    J Pharmacol Exp Ther; 1997 Jul; 282(1):181-91. PubMed ID: 9223553
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ex vivo studies with iloperidone (HP 873), a potential atypical antipsychotic with dopamine D2/5-hydroxytryptamine2 receptor antagonist activity.
    Szczepanik AM; Brougham LR; Roehr JE; Conway PG; Ellis DB; Wilmot CA
    J Pharmacol Exp Ther; 1996 Aug; 278(2):913-20. PubMed ID: 8768747
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity.
    Leysen JE; Janssen PM; Megens AA; Schotte A
    J Clin Psychiatry; 1994 May; 55 Suppl():5-12. PubMed ID: 7520908
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pyrrolo[1,3]benzothiazepine-based serotonin and dopamine receptor antagonists. Molecular modeling, further structure-activity relationship studies, and identification of novel atypical antipsychotic agents.
    Campiani G; Butini S; Fattorusso C; Catalanotti B; Gemma S; Nacci V; Morelli E; Cagnotto A; Mereghetti I; Mennini T; Carli M; Minetti P; Di Cesare MA; Mastroianni D; Scafetta N; Galletti B; Stasi MA; Castorina M; Pacifici L; Vertechy M; Di Serio S; Ghirardi O; Tinti O; Carminati P
    J Med Chem; 2004 Jan; 47(1):143-57. PubMed ID: 14695828
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Involvement of 5-HT2A receptors in the elevation of rat serum corticosterone concentrations by quipazine and MK-212.
    Hemrick-Luecke SK; Fuller RW
    Eur J Pharmacol; 1996 Sep; 311(2-3):207-11. PubMed ID: 8891601
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differential effects of antipsychotic drugs on serotonin-1A receptor-mediated disruption of prepulse inhibition.
    van den Buuse M; Gogos A
    J Pharmacol Exp Ther; 2007 Mar; 320(3):1224-36. PubMed ID: 17194799
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro characterization of SLV308 (7-[4-methyl-1-piperazinyl]-2(3H)-benzoxazolone, monohydrochloride): a novel partial dopamine D2 and D3 receptor agonist and serotonin 5-HT1A receptor agonist.
    Glennon JC; Van Scharrenburg G; Ronken E; Hesselink MB; Reinders JH; Van Der Neut M; Long SK; Feenstra RW; McCreary AC
    Synapse; 2006 Dec; 60(8):599-608. PubMed ID: 17001660
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Role of serotonin and dopamine receptors in the mechanism of action of haloperidol and pirenperone].
    Maĭmets MO; Vasar EE; Nurk AM; Allikmets LKh
    Farmakol Toksikol; 1985; 48(2):15-8. PubMed ID: 3996566
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vitro and in vivo characterization of the dopamine D4 receptor, serotonin 5-HT2A receptor and alpha-1 adrenoceptor antagonist (R)-(+)-2-amino-4-(4-fluorophenyl)-5-[1-[4-(4-fluorophenyl)-4-oxobutyl] pyrrolidin-3-yl]thiazole (NRA0045).
    Okuyama S; Chaki S; Yoshikawa R; Suzuki Y; Ogawa S; Imagawa Y; Kawashima N; Ikeda Y; Kumagai T; Nakazato A; Nagamine M; Tomisawa K
    J Pharmacol Exp Ther; 1997 Jul; 282(1):56-63. PubMed ID: 9223539
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacological profile of SCH39166: a dopamine D1 selective benzonaphthazepine with potential antipsychotic activity.
    Chipkin RE; Iorio LC; Coffin VL; McQuade RD; Berger JG; Barnett A
    J Pharmacol Exp Ther; 1988 Dec; 247(3):1093-102. PubMed ID: 2905002
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Elevation of serum corticosterone concentrations in rats by pergolide and other dopamine agonists.
    Fuller RW; Snoddy HD
    Endocrinology; 1981 Oct; 109(4):1026-32. PubMed ID: 6116593
    [No Abstract]   [Full Text] [Related]  

  • 40. Neuropharmacology of zotepine, an antimanic drug: a potent blocker of D2 and 5-HT2 receptors of human brain.
    Kanba S; Yagi G; Oguchi E; Nakaki T; Kato R; Richelson E
    Jpn J Psychiatry Neurol; 1991 Mar; 45(1):133-4. PubMed ID: 1684393
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.